Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.
Inventiva reports preliminary 2025¹ fiscal year financial results Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the developmen...
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹ Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 2025Réalisation d’une offre au public aux États-Unis pour un produit brut total d’environ 172,5 millions de dollars (149 millions d’euros)3Horizon de trésorerie prévue jusqu’au milieu du premier trimestre 20274 Daix (France), New York City (New York, Etats-Unis), le 17 février 2026 – (Euronext Paris and Nasdaq :IVA) (« Inventiva » ou ...
Heineken N.V. successfully places €1.1 billion of Notes Heineken N.V. successfully places €1.1 billion of Notes Amsterdam, 16 February 2026 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) announced that it has successfully placed €1.1 billion of Notes across two tranches today. €550 million 8-year Notes with a coupon of 3.375%, and€550 million 12-year Notes with a coupon of 3.875%. The Notes will be issued under the Company's Euro Medium Term Note Programme and will be listed on the Luxembourg Stock Exchange. The proceeds from the Notes issuance will be used for general corporate purpo...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 16 February 2026 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the second €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2026. From 12 February 2026 up to and including 13 February 2026 a total of 49,598 shares were repurchased on exchange at an average price of € 79.07. During the same period, 29,60...
Heineken N.V. announces second tranche of its €1.5 billion share buyback programme Heineken N.V. announces second tranche of its €1.5 billion share buyback programme Amsterdam, 12 February 2026 – Heineken N.V. (HEINEKEN) (EURONEXT:HEIA; OTCQX: HEINY) announces the start of the second €750 million tranche of its €1.5 billion two-year share buyback programme as communicated on 12 February 2025. Heineken Holding N.V. (Heineken Holding), HEINEKEN's majority shareholder, will participate pro rata to its shareholding in HEINEKEN's share buyback programme on a daily basis, pursuant to an agreem...
ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...
Rdos. 4T'25 vs 4T'24: Ventas: 23.490 M euros (+0,9% vs +0,8% BS(e) y +0,4% consenso); EBIT: 994,0 M euros (+3,8% vs -4,3% BS(e) y -4,2% consenso); BDI: 577,0 M euros (+51,8% vs +55,3% BS(e) y +57,4% consenso); Rdos. 2025 vs 2024: Ventas: 92.352 M euros (+3,4% vs +3,3% BS(e) y +3,2% consenso); EBIT: 3.734 M euros (+3,5% vs +1,4% BS(e) y +1,4% consenso); BDI: 2.263 M euros (+28,3% vs +29,0% BS(e) y +29,5% consenso).
Heineken's FY25 top line and operating profit figures were slightly better than our forecasts with operating profit in absolute terms in line with consensus. Heineken guides again for sizeable savings efforts in FY26 with operating profit growth guidance calling for a 2-6% range (vs our and consensus forecasts of c. 5%). We still appreciate Heineken for the sizeable self-help initiatives which should support organic earnings growth in the coming years, but acknowledge that the bumpier volume evo...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENDESA, INDRA, SANTANDER, SECTOR SEGUROS, TELEFÓNICA. EUROPA: AHOLD DELHAIZE, BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El Ibex mantiene los 18.100 puntos Ligeras caídas en los mercados en una jornada de transición a la espera de l...
HEINEKEN N.V. REPORTS 2025 FULL YEAR RESULTS Amsterdam, 11 February 2026 HEINEKEN N.V. REPORTS 2025 FULL YEAR RESULTS Well-balanced performance in challenging market conditions IFRS Measures BEIA Measures(in € million) Total growth (in € million) Organic growthRevenue 34,257 -4.7% Revenue (beia) 34,395 0.2%Net revenue 28,753 -3.6% Net revenue (beia) 28,890 1.6%Operating profit 3,406 -3.2% Operating profit (beia) 4,385 4.4%Operating profit margin 11.8% 5 bps Operating profit (beia) margin 15.2% 41 bpsNet profit 1,885 92.7% Net profit (beia) 2,662 4.9%Diluted EPS 3....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.